Young T cells age during a redirected anti-tumor attack: Chimeric antigen receptor-provided dual costimulation is half the battle

Frontiers in Immunology

Volumn 4, Issue JUN, 2013, Pages

  Hombach, Andreas A ^a,b   Abken, Hinrich ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Adoptive cell therapy; Cd28; Chimeric antigen receptor; Memory T cells; Ox40

Indexed keywords

CD134 ANTIGEN; CD19 ANTIGEN; CD28 ANTIGEN; CD57 ANTIGEN; CD7 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL AGING; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL HOMING; CELLULAR IMMUNITY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; T LYMPHOCYTE;

EID: 84883773593     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00135     Document Type: Article

References (23)

1. Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828. doi:10.1182/blood-2011-04-348540
2. Bromley, S. K., Thomas, S. Y., and Luster, A. D. (2005). Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. 6, 895-901. doi:10.1038/ni1240
3. Chattopadhyay, P. K., Betts, M. R., Price, D. A., Gostick, E., Horton, H., Roederer, M., et al. (2009). The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J. Leukoc. Biol. 85, 88-97. doi:10.1189/jlb.0208107
4. Eshhar, Z. (2008). The T-body approach: redirecting T cells with antibody specificity. Handb. Exp. Pharmacol. 181, 329-342. doi:10.1007/978-3-540-73259-4_14
5. Gilham, D. E., Debets, R., Pule, M., Hawkins, R. E., and Abken, H. (2012). CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol. Med. 18, 377-384. doi:10.1016/j.molmed.2012.04.009
6. Gross, G., and Eshhar, Z. (1992). Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J. 6, 3370-3378.
7. Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518. doi:10.1056/NEJMoa1215134
8. Hombach, A. A., and Abken, H. (2011). Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int. J. Cancer 129, 2935-2944. doi:10.1002/ijc.25960
9. Hombach, A. A., Chmielewski, M., Rappl, G., and Abken, H. (2013). Adoptive immunotherapy with redirected T cells produces CCR7(-) cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum. Gene Ther. 24, 259-269. doi:10.1089/hum.2012.247
10. Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73. doi:10.1126/scitranslmed.3002842
11. Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., Cardones, A. R., Finkelstein, S. E., et al. (2005). Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U.S.A. 102, 9571-9576. doi:10.1073/pnas.0503726102
12. Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720. doi:10.1182/blood-2011-10-384388
13. Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453-1464. doi:10.1038/mt.2009.83
14. Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., et al. (2011). Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human t cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719-4730. doi:10.1158/1078-0432.CCR-11-0351
15. Moschovakis, G. L., and Förster, R. (2012). Multifaceted activities of CCR7 regulate T-cell homeostasis in health and disease. Eur. J. Immunol. 42, 1949-1955. doi:10.1002/eji.201242614
16. Müller, G., and Lipp, M. (2003). Shaping up adaptive immunity: the impact of CCR7 and CXCR5 on lymphocyte trafficking. Microcirculation 10, 325-334. doi:10.1080/mic.10.3-4.325.334
17. Parente-Pereira, A. C., Burnet, J., Ellison, D., Foster, J., Davies, D. M., van der Stegen, S., et al. (2011). Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 31, 710-718. doi:10.1007/s10875-011-9532-8
18. Rappl, G., Riet, T., Awerkiew, S., Schmidt, A., Hombach, A. A., Pfister, H., et al. (2012). The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells. PLoS ONE 7:e30713. doi:10.1371/journal.pone.0030713
19. Rogers, P. R., Song, J., Gramaglia, I., Killeen, N., and Croft, M. (2001). OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15, 445-455. doi:10.1016/S1074-7613(01)00191-1
20. Sallusto, F., Lenig, D., Förster, R., Lipp, M., and Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712. doi:10.1038/44385
21. Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826. doi:10.1172/JCI46110
22. Song, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., et al. (2011). In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71, 4617-4627. doi:10.1158/0008-5472.CAN-11-0422
23. Weber, J., Atkins, M., Hwu, P., Radvanyi, L., Sznol, M., and Yee, C. (2011). White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin. Cancer Res. 17, 1664-1673. doi:10.1158/1078-0432.CCR-10-2272